Trials / Completed
CompletedNCT02148718
Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
Rapidity of Onset of Response to Adalimumab in Luminal Crohn's Disease (RAPIDA Study)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the rapidity of onset of clinical response to adalimumab therapy in patients with luminal Crohn's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | adalimumab | Adalimumab pre-filled syringe, administered by subcutaneous injection |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2016-08-01
- Completion
- 2017-01-01
- First posted
- 2014-05-28
- Last updated
- 2018-03-01
- Results posted
- 2017-08-29
Source: ClinicalTrials.gov record NCT02148718. Inclusion in this directory is not an endorsement.